Cholangiocarcinoma News

CCA Summit Live from ASCO 2021

Videos — June 9, 2021

Featuring:

Mitesh J. Borad, MD
Associate Professor of Medicine
Mayo Clinic
Phoenix, AZ

On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.

Following his presentation, Dr Borad, the other members of the Program Steering Committee, and attendees of the “CCA Summit Live from ASCO 2021” meeting discussed the abstracts and provided their perspectives on these key presentations.

Related Items

GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.
Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA: NEO-GAP
September 2022, Vol 3, No 3
For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence.
Toripalimab Combined with Gemcitabine and S-1 in the First-Line Treatment of Advanced BTCs
September 2022, Vol 3, No 3
Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal.
PROs with Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Regional Subgroup Analysis of Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
September 2022, Vol 3, No 3
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Efficacy and Safety of Futibatinib in iCCA Harboring FGFR2 Fusions/Rearrangements: Updated Results of the FOENIX-CCA2 Trial
September 2022, Vol 3, No 3
Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements.
Adjuvant GemCis versus CAP in Patients with Resected Lymph Node–Positive eCCA: The STAMP Study
September 2022, Vol 3, No 3
Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
CCA Summit Live from ASCO 2022
By Ghassan K. Abou-Alfa, MD, MBA
Videos
Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: